Loading...
Safety and Efficacy of <scp>Long‐Term</scp> Voclosporin Treatment for Lupus Nephritis in the Phase 3 <scp>AURORA</scp> 2 Clinical Trial
Saxena, Amit; Ginzler, Ellen M.; Gibson, Keisha; Satirapoj, Bancha; Santillán, Adolfina Elizabeth Zuta; Levchenko, Olena; Navarra, Sandra; Atsumi, Tatsuya; Yasuda, Shinsuke; Chavez‐Perez, Nilmo Noel; Arriens, Cristina; Parikh, Samir V.; Caster, Dawn J.; Birardi, Vanessa; Randhawa, Simrat; Lisk, Laura; Huizinga, Robert B.; Teng, Y. K. Onno
Journal Title
Arthritis & Rheumatology
Keywords
Readers/Advisors
Journal Title
Term and Year
Publication Date
2023-09-15
Book Title
Publication Volume
76
Publication Issue
1
Publication Begin
59
Publication End
67
Number of pages
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Objective: AURORA 2 evaluated the long-term safety, tolerability, and efficacy of voclosporin compared to placebo in patients with lupus nephritis (LN) receiving an additional two years of treatment following completion of the one-year AURORA 1 study.
Methods: Enrolled patients continued their double-blinded treatment of voclosporin or placebo randomly assigned in AURORA 1, in combination with mycophenolate mofetil and low-dose glucocorticoids. The primary objective was safety assessed with adverse events (AEs) and biochemical and hematological assessments. Efficacy was measured by renal response.
Results: A total of 216 patients enrolled in AURORA 2. Treatment was well tolerated with 86.1% completing the study and no unexpected safety signals. AEs occurred in 86% and 80% of patients in the voclosporin and control groups, respectively, with an AE profile similar to that seen in AURORA 1, albeit with reduced frequency. Investigator reported AEs of both glomerular filtration rate (GFR) decrease and hypertension occurred more frequently in the voclosporin than the control group (10.3% vs 5.0%, and 8.6% vs 7.0%, respectively). Mean corrected estimated GFR (eGFR) was within the normal range and stable in both treatment groups. eGFR slope over the two-year period was -0.2 mL/min/1.73 m2 (95% confidence interval [CI] -3.0 to 2.7) in the voclosporin group and -5.4 mL/min/1.73 m2 (95% CI -8.4 to -2.3) in the control group. Improved proteinuria persisted across three years of treatment, leading to more frequent complete renal responses in patients treated with voclosporin (50.9% vs 39.0%; odds ratio 1.74; 95% CI 1.00-3.03).
Conclusion: Data demonstrate the safety and efficacy of long-term voclosporin treatment over three years of follow-up in patients with LN.
Citation
Saxena A, Ginzler EM, Gibson K, Satirapoj B, Santillán AEZ, Levchenko O, Navarra S, Atsumi T, Yasuda S, Chavez-Perez NN, Arriens C, Parikh SV, Caster DJ, Birardi V, Randhawa S, Lisk L, Huizinga RB, Teng YKO. Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial. Arthritis Rheumatol. 2024 Jan;76(1):59-67. doi: 10.1002/art.42657. Epub 2023 Sep 15. PMID: 37466424.